Mutant-selective degradation by BRAF-targeting PROTACs

by Shanique Alabi, Saul Jaime-Figueroa, Zhan Yao, Yijun Gao, John Hines, Kusal T. G. Samarasinghe, Lea Vogt, Neal Rosen, Craig M. Crews
Published 2021

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

by Alison E. Smith, Emanuela Ferraro, Anton Safonov, Cristina Bernado Morales, Enrique J. Arenas Lahuerta, Qing Li, Amanda Kulick, Dara Ross, David B. Solit, Elisa de Stanchina, Jorge Reis-Filho, Neal Rosen, Joaquín Arribas, Pedram Razavi, Sarat Chandarlapaty
Published 2021

Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers

by Ninghui Mao, Zeda Zhang, Young Sun Lee, Danielle Choi, Aura Agudelo Rivera, Dan Li, Cindy Lee, Samuel Haywood, Xiaoping Chen, Qing Chang, Guotai Xu, Hsuan-An Chen, Elisa de Stanchina, Charles Sawyers, Neal Rosen, Andrew C. Hsieh, Yu Chen, Brett S. Carver
Published 2021

Anti-tumor effects of an ID antagonist with no observed acquired resistance

by Paulina M. Wojnarowicz, Marta Garcia Escolano, Yun-Han Huang, Bina Desai, Yvette Chin, Riddhi Shah, Sijia Xu, Saurabh Yadav, Sergey Yaklichkin, Ouathek Ouerfelli, Rajesh Kumar Soni, John Philip, David C. Montrose, John H. Healey, Vinagolu K. Rajasekhar, William A. Garland, Jeremy Ratiu, Yuan Zhuang, Larry Norton, Neal Rosen, Ronald C. Hendrickson, Xi Kathy Zhou, Antonio Iavarone, Joan Massague, Andrew J. Dannenberg, Anna Lasorella, Robert Benezra
Published 2021